AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($56.3B)

靜態數據（加載即時財務…）

Immunology (45%)

Aesthetics/Neuroscience (25%)

Oncology (15%)

Eye Care & Other (15%)

業務部門構成與主要客戶

產品詳情

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

供應鏈關係

競爭對手

Eli Lilly and Company

Immunology and oncology drugs

影響: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

影響: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

影響: Major pharma rival

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 AbbVie Inc. 的 AI 供應鏈分析。

企業資訊

總部

North Chicago, Illinois, USA

成立時間

2013

員工人數

50,000+

官網

abbvie.com

行業概況 — 제약 / 바이오

行業新聞